前往化源商城

品牌现货直购
供应商：我要出现这里

查看所有供应商和价格请点击：

125317-39-7生产厂家

125317-39-7价格

相关CAS号：
106837-96-1 1247771-97-6
1248410-54-9 1249265-45-9
934744-56-6 1866153-29-8
1250536-67-4 933750-99-3
1182914-87-9 1485234-47-6

125317-39-7

125317-39-7结构式
125317-39-7结构式

化源商城直购

中文名 酒石酸长春瑞滨
英文名 vinorelbine L-tartrate
中文别名 酒石酸长春瑞滨/生物碱
Vinorelbine dittrate (KW-2307) 酒石酸长春瑞滨,S4269
酒石酸长春瑞宾/重酒石酸长春瑞宾
酒石酸长春瑞宾
二酒石酸盐长春瑞宾
重酒石酸长春瑞滨
酒石酸长春瑞滨 Vinorelbine Ttrate
长春瑞宾双酒石酸盐
长春瑞滨酒石酸盐
酒石酸长春瑞滨,10 MM DMSO 溶液
长春瑞滨
酒石酸长春瑞滨/D1A
化合物:Vinorelbine dittrate
长春瑞宾双酒石酸盐,酒石酸长春瑞宾
(3,3A1R,4R,5S,5,10BR)-4-乙酰氧基-3A-乙基-9-((8R)-4-乙基-8-(甲氧基羰基)-1,3,6,7,8,9-六氢-2,6-METHANOAZECINO[4,3-B]吲哚-8-基)-5-羟基-8-甲氧基-6-甲基-3A,3A1,4,5,5A,6,11,12-八氢-1H-吲哚嗪并[8,1-CD]咔唑-5-甲酸甲酯 双((2R,3R)-2,3-二羟基琥珀酸盐)
酒石酸长春瑞滨, (HPLC)
有丝分裂抑制剂(HELA细胞增殖抑制剂)
化合物：Vinorelbine dittrate
酒石酸长春瑞滨对照品
洒石酸长春瑞宾
酒石酸长春瑞滨 标准品
长春瑞滨酒石酸酯(盐)
酒石酸长春瑞滨长春瑞宾双酒石酸盐
重酒石酸长春瑞宾(标准品)
酒石酸长春瑞滨(标准品)
酒石酸长春瑞滨 50NG
Vinorelbine dittrate (KW-2307) 酒石酸长春瑞滨，S4269
VINORELBINE TTRATE (NAVELBINE),MITOTIC MICROTUBULE拮抗剂
英文别名 Vinorelbine Bittate
methyl (2β,3β,4β,5α,12β,19α)-4-(acetyloxy)-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxybutanedioate) (salt)
Aspidospermidine-3-cboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12R,19a)-, (2R,3R)-2,3-dih
MFCD03613607
3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE [R-(R*,R*)-DIHYDROXYBUTANEDIOATE (1:2) SALT]
Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxysuccinate (1:2)
Vinoreline Ttrate
Vinorelbine ttrate //BP
C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:2) (salt)
Vinorelbine dittate
VINORELBINE TTRATE
Nor-5'-anhydrovinblastine dittrate
VINORELBINEDITTRATE SALT HYDRATE
Vinorelbine Dittrate salt hydrate, (HPLC)
butanedioate(1:2)
3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine ttrate, KW-2307, NVB, Navelbine ttrate
Vinorelbine hydrate dittrate salt
Vinorelbine ttrate CRS
VINORELBINE TTRATE STANDD
Vinorelbine tartrate
Vinorelbine DittrateQ: What is Vinorelbine Dittrate Q: What is the CAS Number of Vinorelbine Dittrate Q: What is the storage condition of Vinorelbine Dittrate Q: What e the applications of Vinorelbine Dittrate
VINORELBINE TTRATE, NAVELBINE
(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-cboxylicacidmethylester
inorelbine ttrate
Aspidospermidine-3-cboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12b,19a)-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (salt)
methyl (2β,3β,4β,5α,12β,19α)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxybutanedioate (1:2)
6-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxybutanedioate) (salt)
VINORELBINE DITTRATE
2,3-Dihydroxybutandisäure-methyl-(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-5-carboxylat(2:1)
aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, m
Methyl (3,3a1R,4R,5S,5,10bR)-4-acetoxy-3a-ethyl-9-((8R)-4-ethyl-8-(methoxycbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]cbazole-5-cboxylate bis((2R,3R)-2,3-dihydroxysuccinate)
3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine Dittrate
KW-2307
VINORELBINE BITTRATE
ethyl ester, (2β,3β,4β,5α,12β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt)
Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxysuccinate) (salt)
Methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(1R,12S,14R)-16-ethyl-12-(Methoxycbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3,4,5,7,15-pentaen-12-yl]-10-hydroxy-5-Methoxy-8-Methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0
Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-me
 thoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxysuccinate (1:2)
3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine (R-(R*,R*))-2,3-dihydroxybutanedioate (1:2) (salt)
methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy
Vinorelbine dittrate, Vinorelbine bittrate, VRLB,KW – 2307 NVB
VinorelbineTtrate28
Vinorelbine ditartrate
Methyl (3aR,4R,5S,5aR,10bR,13aR)-4-acetoxy-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxysuccinate) (salt)
Vinorelbine ttrate (Navelbine), mitotic microtubule antagonist
Chanhun Ruibin Ttrate
NAVELBINE
5'-NORANHYDROVINOBLASTINE TTRATE
aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt)
VINORELBINE RELATED COMPOUND A4-O-DEACETYLVINORELBINE TTRATE STANDD
methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxybutanedioate) (salt)
Vinorelbine-D3 DittrateQ: What is Vinorelbine-D3 Dittrate Q: What is the CAS Number of Vinorelbine-D3 Dittrate
vinorelbine L-ttrate
Vinorelbin trate
lbine Dittrate
Vinorelbine Ditartarate
VINORELBINE(RG)
methyl (2β,3β,4β,5α,12β,19α)-4-(acetyloxy)-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-1
Nor-5'-anhydrovinblastine ditartrate
Vinorelbine dittrate (KW-2307)
VINORELBINE DITTIC ACID
NAVELBINE TTRATE
Vinorelbine ditartrate salt
Vinorelbin Ttrate
Eunades
5μ-Noranhydrovinoblastine ttrate, KW-2307, Navelbine ttrate, NVB, 3μ,4μ-Didehydro-4μ-deoxy-Cμ-norvincaleukoblastine [R-(R*,R*)-dihydroxybutanedioate (1:2)salt]
Pacilitaxel
Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, m ;ethyl ester, (2β,3β,4β,5α,12β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt)
-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxybutanedioate) (salt)
VINORELBINE DITTRATE SALT
Vinorelbine Bittrate (10mM in DMSO)
Navelbine dittrate
c’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxy
acide 2,3-dihydroxybutanedioïque - (3aR,4R,5S,5aR,10bR,13aR)-4-(acétyloxy)-3a-éthyl-9-[(12S,14R)-16-éthyl-12-(méthoxycarbonyl)-1,10-diazatétracyclo[12.3.1.0.0]octadéca-3(11),4,6,8,15-pentaén-12-yl]-5-hydroxy-8-méthoxy-6-méthyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate de méthyle (2:1)
Vinorelbine dittrate salt hydrate,3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine ttrate, KW-2307, NVB, Navelbine ttr
Vinorelbine
Atorvastatin Impurity
描述 Vinorelbine ditartrate 是一种抗有丝分裂剂,能够抑制 Hela 细胞的增殖,IC50值为 1.25 nM。
相关类别
体外研究 长春瑞滨(0.5-5nM)在浓度为1.25nM时抑制细胞增殖50％(IC50)。浓度为8 nM的长春瑞滨时,没有细胞处于后期[1]。长春瑞滨时间依赖性地诱导雄激素依赖性(AD)和非依赖性(AI)前列腺癌细胞系中的p53和p21WAFI/CIP1表达。长春瑞滨以浓度依赖性方式刺激报告基因[2]。
体内研究 长春瑞滨治疗后,第一次中性粒细胞过多发生在狗的第一次(4只狗),第二次(1)或第六次(1)长春瑞滨治疗后[3]。长春瑞滨在携带肿瘤的猫中每周耐受一次,MTD为11.5 mg/m2 [4]。
动物实验 根据该研究的定义，将VRL1在0.9％NaCl中稀释至1.5mg / mL的浓度，并在5分钟内进行IV。预期的治疗间隔为7天，最多4次治疗。在每周接受4次剂量后，猫有资格每2周继续接受VRL治疗。
参考文献

[1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32.

[2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73.

[3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9.

[4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8.
密度 1.36g/cm3
熔点 181-183°C
分子式 C53H66N4O20
分子量 1079.106
精确质量 1078.427002
PSA 363.99000
LogP 0.44920
外观性状 白色至灰白色结晶粉末
折射率 1.675
储存条件

密封、在2 ºC -8 ºC下保存

稳定性

如果遵照规格使用和储存则不会分解，未有已知危险反应

水溶解性 H2O: 10 mg/mL
分子结构

1、摩尔折射率：无可用的

2、摩尔体积（cm3/mol）：无可用的

3、等张比容（90.2K）：无可用的

4、表面张力（dyne/cm）：无可用的

5、介电常数：无可用的

6、极化率（10-24cm3）：无可用的

7、单一同位素质量：1078.427041 Da

8、标称质量：1078 Da

9、平均质量：1079.1059 Da
计算化学

1、 疏水参数计算参考值（XlogP）：

2、 氢键供体数量：10

3、 氢键受体数量：23

4、 可旋转化学键数量：16

5、 互变异构体数量：

6、 拓扑分子极性表面积（TPSA）：364

7、 重原子数量：77

8、 表面电荷：0

9、 复杂度：1820

10、同位素原子数量：0

11、确定原子立构中心数量：11

12、不确定原子立构中心数量：1

13、确定化学键立构中心数量：0

14、不确定化学键立构中心数量：0

15、共价键单元数量：3

更多

1. 性状：白色粉末

2. 密度（g/mL,20℃）：未确定

3. 相对蒸汽密度（g/mL,空气=1）：未确定

4. 熔点（ºC）：181-183

5. 沸点（ºC,常压）：未确定

6. 沸点（ºC,KPa）：未确定

7. 折射率：未确定

8. 闪点（ºC）：未确定

9. 比旋光度（º）：未确定

10. 自燃点或引燃温度（ºC）：未确定

11. 蒸气压（Pa,20ºC）：未确定

12. 饱和蒸气压（KPa,20ºC）：未确定

13. 燃烧热（KJ/mol）：未确定

14. 临界温度（ºC）：未确定

15. 临界压力（KPa）：未确定

16. 油水（辛醇/水）分配系数的对数值：未确定

17. 爆炸上限（%,V/V）：未确定

18. 爆炸下限（%,V/V）：未确定

19. 溶解性：水：10mg/ml

毒理学数据:

生殖毒性：受孕7-16天的大鼠静脉注射TDLo：2mg/kgSEX/DURATION；

CHEMICAL IDENTIFICATION

RTECS NUMBER :
RD2535000
CAS REGISTRY NUMBER :
125317-39-7
LAST UPDATED :
199706
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C45-H54-N4-O8.2C4-H6-O6
MOLECULAR WEIGHT :
1079.23

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
2 mg/kg
SEX/DURATION :
female 7-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 27,1375,1993

危害码 (欧洲) Xi:Irritant
风险声明 (欧洲) R43
安全声明 (欧洲) 26-36
危险品运输编码 NONH for all modes of transport
WGK德国 3
海关编码 2942000000
海关编码 2942000000
本网页内容来自不同专业数据源，如对内容有疑义，欢迎联系service1@chemsrc.com。

【125317-39-7】化源网提供CAS号/CAS登录号125317-39-7，CAS No.:125317-39-7的msds、结构式、性质、英文名、生产厂家、作用/用途、分子式/化学式、密度、沸点、熔点等。CAS号查询125317-39-7上化源网，专业又轻松。
标题：125317-39-7_CAS号:125317-39-7_CAS No.:125317-39-7 - 化源网 地址：https://m.chemsrc.com/baike/828709.html

首页 |  期刊大全 |  MSDS查询 |  化工产品分类 |  生物活性化合物 |  关于我们 |  免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2026 ChemSrc All Rights Reserved